The recommendations include:

• developing additional guidance on:
  • the roles and responsibilities of companies involved in the manufacture of medicines;
  • controlling impurities;
  • good manufacturing practice (GMP);
  • sampling and testing.
• improving communication with patients and healthcare professionals;
• expanding cooperation with international partners;
• further developing information technology systems.

These recommendations apply to all medicines.

Source:

EMA: Nitrosamin Impurities